Kane Biotech Inc.

OTCPK:KNBI.F Stock Report

Market Cap: US$9.6m

Kane Biotech Management

Management criteria checks 2/4

Kane Biotech's CEO is Rob Huizinga, appointed in Feb 2024, has a tenure of 1.25 years. directly owns 1.76% of the company’s shares, worth $168.37K. The average tenure of the management team and the board of directors is 2.2 years and 6.7 years respectively.

Key information

Rob Huizinga

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownership1.8%
Management average tenure2.2yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

CEO

Rob Huizinga (59 yo)

1.3yrs

Tenure

Dr. Robert B. Huizinga, also known as Rob, Ph.D. RN NNC, M.Sc. (Epi), CNeph(C), served as an Executive Vice President of Research at Aurinia Pharmaceuticals Inc. since June 2020 until October 31, 2022. He...

Leadership Team

NamePositionTenureCompensationOwnership
Ray Dupuis
Chief Financial Officer7.7yrsCA$231.39k0.65%
$ 62.3k
Robert Huizinga
Interim CEO1.3yrsno data1.76%
$ 168.4k
Gregory Schultz
Chief Scientific Officer & Member of Scientific Advisory Board3.1yrsno datano data
Lorne Gorber
Investor Relationsno datano datano data
Wendy Nachtigall
Director of Marketingno datano datano data
Lori Christofalos
Chief Quality Officer1yrno datano data
Nicole Sendey
Investor Relations Adviserno datano datano data

2.2yrs

Average Tenure

Experienced Management: KNBI.F's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Huizinga
Interim CEO6.7yrsno data1.76%
$ 168.4k
Gregory Schultz
Chief Scientific Officer & Member of Scientific Advisory Board3.3yrsno datano data
Georges Morin
Independent Director5yrsCA$41.53k0.090%
$ 8.6k
Philip Renaud
Vice Chairman14.7yrsCA$44.73k21.82%
$ 2.1m
Rashieda Gluck
Member of Scientific Advisory Board6.7yrsCA$13.30kno data
Gordon Guay
Chairman of Scientific Advisory Board6.7yrsno datano data
John Coleman
Independent Director1.5yrsCA$2.25kno data

6.7yrs

Average Tenure

Experienced Board: KNBI.F's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 06:03
End of Day Share Price 2025/05/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.